Effects of different contrast on circulation endothelial microparticles in type 2 diabetic patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14005183

Enrollment

Unknown

Registered

2014-08-20

Start date

2014-09-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

Diabetes mellitus Group 1:100~200 ml Iodixanol during PCI

Diabetes mellitus Group 2:100~200 ml Iohexol during PCI

Non-Diabetes Mellitus Group:100~200 ml Iohexol during PCI

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: Stable coronary heart disease patients with PCI treatment,including diabetes mellitus and non-diabetes mellitus patients.

Exclusion criteria

Exclusion criteria: Elevated serum creatinine levels in patients with all causes; ACS patients with elevated troponin I; patients older than 75 years old; various causes lead to elevated CRP disorders, such as recent infection, trauma, rheumatic activities; patients merged with valvular disease significantly affect cardiac hemo dynamics; merger disorders, such as cancer, thyroid disease, tuberculosis or taking hormones; patients unable or unwilling to collaborate.

Design outcomes

Primary

Measure	Time frame
Circulation Endothelial Microparticles;The ratio of immune phenotype;	—

Countries

China

Contacts

Public ContactShu Meng

msdoctor@126.com+86 13916005250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026